Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQTBRM)

• Drug Name: [3H]CGP27492 Drug Info
• Synonyms: 3-Aminopropylphosphinic acid; 3-aminopropylphosphinic acid; 3-Aminopropanephosphinic acid; CGP-27492; Cgp 27492; 3-Aminopropylphosphonous acid; Phosphinic acid, (3-aminopropyl); 3-aminopropyl-hydroxy-oxophosphanium; CHEMBL112203; [3H]3-APPA; [3H]-3-APPA; Cgp 27 492; [3H]-CGP27492; AC1O3S7O; SCHEMBL341549; GTPL5381; GTPL1081; BDBM24184; CTK8G4752; (3-Amino-propyl)-phosphinic acid; ZTHNRNOOZGJLRR-UHFFFAOYSA-N; MolPort-019-939-257; CGP27492; 3-aminopropyl-hydroxy-oxo-phosphonium; BN0804; PDSP2_001468; PDSP1_001484; FCH933647; 3-aminopropylphosphinic; [3H]-CGP27492

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6335948
  CAS Number: CAS 103680-47-3
  TTD Drug ID: DMQTBRM

Molecule-Related Drug Atlas

Drug(s) Targeting Gamma-aminobutyric acid B receptor (GABBR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[4]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[5]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[6]
Progabide	DM671NG	Depression	6A70-6A7Z	Approved	[7]
Arbaclofen placarbil	DMO628K	Fragile X syndrome	LD55	Phase 3	[8]
[3H](R)-(-)-baclofen	DMLRHM5	Multiple sclerosis	8A40	Phase 3	[9]
Arabaclofen	DMZB9RI	Fragile X syndrome	LD55	Phase 3	[10]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[11]
SGS742	DM5XYFH	Schizophrenia	6A20	Phase 2	[12]
SSTarbaclofen	DMRGTZ2	Autism spectrum disorder	6A02	Phase 2	[13]

Drug(s) Targeting GABA(A) receptor alpha-1 (GABRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[14]
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[15]
Methoxyflurane	DML0RAE	Anaesthesia	9A78.6	Approved	[14]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[14]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[16]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[14]
Hexobarbital	DMQ314B	Anaesthesia	9A78.6	Approved	[14]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[17]
Meprobamate	DMHM93Y	Anxiety		Approved	[14]
Zaleplon	DMGFWSM	Insomnia	7A00-7A0Z	Approved	[5]

Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[14]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[18]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[17]
Clonazepam	DMTO13J	Absence epilepsy		Approved	[19]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[20]
Alpidem	DMN7Y9K	Anxiety disorder	6B00-6B0Z	Approved	[21]
Moxidectin	DMYGHX5	Onchocerciasis	1F6A	Approved	[22]
DP-VPA	DMGOXPQ	Bipolar disorder	6A60	Approved	[23]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[18]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Inhibitor	[2]
Gamma-aminobutyric acid B receptor (GABBR)	TTDCVZW	GABR1_HUMAN; GABR2_HUMAN	Inhibitor	[3]
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5381).
• [2] Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312.
• [3] Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993).
• [4] Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
• [7] Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
• [8] Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
• [10] Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
• [11] 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
• [12] SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
• [13] Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.
• [14] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [15] Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
• [16] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [17] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [18] Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
• [19] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [20] Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
• [21] Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
• [22] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [23] DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
• [24] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.